| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: Targeted Oncology |
| Recipient: You |
| Company: OncLive |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: AstraZeneca |
| Recipient: You |
| Company: Jazz Pharmaceuticals |
| Recipient: You |
| Company: OncoCyte |
| Recipient: You |
| Company: Sanofi |
| Recipient: You |
| Company: Mirati Therapeutics |
| Recipient: You |
| Company: Daiichi Sankyo/Astra Zeneca |
| Recipient: You |
| Company: Takeda |
| Recipient: You |
| Company: Gilead Sciences |
| Recipient: You |
| Company: Janssen |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Helsinn Therapeutics |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Jounce Therapeutics |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Mirati Therapeutics |
| Recipient: Your Institution |
| Company: Daiichi Sankyo |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: RTI International |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Chugai Pharma |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|